Tolvaptan study shows promising results in polycystic kidney disease. PDF Print
Science Daily (ASN): The multicenter study found tolvaptan demonstrated a nearly 50 percent reduction in the rate of increase in total kidney volume (a measurement of kidney cyst growth) in ADPKD patients over the study period, compared to placebo.

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.